CY1111154T1 - Ενωσεις ιμιδαζο (1,2-α) πυριδινης ως αναστολεις του vegf-r2 - Google Patents
Ενωσεις ιμιδαζο (1,2-α) πυριδινης ως αναστολεις του vegf-r2Info
- Publication number
- CY1111154T1 CY1111154T1 CY20111100115T CY111100115T CY1111154T1 CY 1111154 T1 CY1111154 T1 CY 1111154T1 CY 20111100115 T CY20111100115 T CY 20111100115T CY 111100115 T CY111100115 T CY 111100115T CY 1111154 T1 CY1111154 T1 CY 1111154T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vegf
- inhibitors
- imidazo
- pyridine compounds
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65598105P | 2005-02-24 | 2005-02-24 | |
| EP06735794A EP1904494B1 (en) | 2005-02-24 | 2006-02-23 | Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111154T1 true CY1111154T1 (el) | 2015-06-11 |
Family
ID=36587138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100115T CY1111154T1 (el) | 2005-02-24 | 2011-02-03 | Ενωσεις ιμιδαζο (1,2-α) πυριδινης ως αναστολεις του vegf-r2 |
Country Status (33)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| WO2008112164A2 (en) | 2007-03-08 | 2008-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| EA201000615A1 (ru) | 2007-10-17 | 2010-12-30 | Новартис Аг | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) |
| GB0810902D0 (en) * | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2010028175A1 (en) | 2008-09-08 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| JP2012506856A (ja) | 2008-10-28 | 2012-03-22 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| TW201124391A (en) | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6430383B2 (ja) * | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| CN104822679B (zh) * | 2012-11-29 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 咪唑并吡啶衍生物 |
| KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
| AU2014365823B2 (en) | 2013-12-16 | 2019-05-02 | Abs Development 1, Inc. | P2X3 and/or P2X2/3 compounds and methods |
| CN103772308B (zh) * | 2013-12-31 | 2015-11-18 | 北京颖泰嘉和生物科技股份有限公司 | 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法 |
| US9988371B2 (en) | 2014-06-03 | 2018-06-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Benzimidazole analogues and related methods |
| DK3169671T3 (da) | 2014-07-17 | 2019-09-23 | Sunshine Lake Pharma Co Ltd | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft |
| CN104163790B (zh) * | 2014-08-19 | 2016-02-10 | 贵州威顿晶磷电子材料股份有限公司 | 一种2-氨基-4-甲基-5溴吡啶的制备工艺 |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2016315881B2 (en) | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| US10160747B2 (en) * | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2019178383A1 (en) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| WO2020142557A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| WO2020144375A1 (en) | 2019-01-11 | 2020-07-16 | Grünenthal GmbH | Substituted pyrrolidine amides iii |
| US11512088B2 (en) * | 2019-01-30 | 2022-11-29 | Avista Pharma Solutions, Inc. | Synthetic process and intermediates |
| CA3128024A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| US12365685B2 (en) | 2019-02-18 | 2025-07-22 | Shenzhen Targetrx, Inc. | Substituted fused aromatic ring derivative, composition and use thereof |
| EP3990458A4 (en) * | 2019-06-25 | 2025-01-08 | Sinopsee Therapeutics | LINKS TO THE TREATMENT OF CANCER |
| CN112778294A (zh) * | 2021-01-07 | 2021-05-11 | 苏州安睿药业有限公司 | 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用 |
| JP7891524B2 (ja) | 2021-08-11 | 2026-07-16 | バイオメア フュージョン，インコーポレイテッド | 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤 |
| MX2024002189A (es) | 2021-08-20 | 2024-06-11 | Biomea Fusion Inc | Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer. |
| WO2024155719A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction |
| WO2025038525A1 (en) * | 2023-08-11 | 2025-02-20 | Bioventures, Llc | Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| CA2374737C (en) | 1999-07-09 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| US6492529B1 (en) * | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
| JP2003313126A (ja) * | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| US7125888B2 (en) * | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003298942A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| WO2005016928A1 (ja) | 2003-08-15 | 2005-02-24 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン誘導体 |
-
2006
- 2006-02-22 DO DO2006000051A patent/DOP2006000051A/es unknown
- 2006-02-23 PE PE2006000219A patent/PE20061098A1/es not_active Application Discontinuation
- 2006-02-23 DE DE602006018615T patent/DE602006018615D1/de not_active Expired - Lifetime
- 2006-02-23 BR BRPI0609047-8A patent/BRPI0609047A2/pt not_active IP Right Cessation
- 2006-02-23 AR ARP060100668A patent/AR056186A1/es not_active Application Discontinuation
- 2006-02-23 NZ NZ584753A patent/NZ584753A/en not_active IP Right Cessation
- 2006-02-23 ES ES06735794T patent/ES2354716T3/es not_active Expired - Lifetime
- 2006-02-23 MX MX2007010326A patent/MX2007010326A/es active IP Right Grant
- 2006-02-23 AU AU2006216710A patent/AU2006216710B2/en not_active Ceased
- 2006-02-23 HR HR20100677T patent/HRP20100677T1/hr unknown
- 2006-02-23 EA EA200701802A patent/EA011691B1/ru not_active IP Right Cessation
- 2006-02-23 WO PCT/US2006/006283 patent/WO2006091671A1/en not_active Ceased
- 2006-02-23 CA CA2599124A patent/CA2599124C/en not_active Expired - Fee Related
- 2006-02-23 EP EP06735794A patent/EP1904494B1/en not_active Expired - Lifetime
- 2006-02-23 PL PL06735794T patent/PL1904494T3/pl unknown
- 2006-02-23 AT AT06735794T patent/ATE490254T1/de active
- 2006-02-23 NZ NZ560402A patent/NZ560402A/en not_active IP Right Cessation
- 2006-02-23 KR KR1020077019338A patent/KR100904938B1/ko not_active Expired - Fee Related
- 2006-02-23 SI SI200630871T patent/SI1904494T1/sl unknown
- 2006-02-23 CN CN2006800060044A patent/CN101128461B/zh not_active Expired - Fee Related
- 2006-02-23 US US11/816,416 patent/US7666879B2/en not_active Expired - Fee Related
- 2006-02-23 PT PT06735794T patent/PT1904494E/pt unknown
- 2006-02-23 JP JP2007557126A patent/JP5055136B2/ja not_active Expired - Fee Related
- 2006-02-23 UA UAA200709559A patent/UA91535C2/ru unknown
- 2006-02-23 TW TW095106022A patent/TW200640924A/zh unknown
- 2006-02-23 DK DK06735794.7T patent/DK1904494T3/da active
- 2006-02-23 RS RS20110042A patent/RS51590B/sr unknown
-
2007
- 2007-07-19 IL IL184717A patent/IL184717A/en not_active IP Right Cessation
- 2007-08-22 CR CR9331A patent/CR9331A/es not_active Application Discontinuation
- 2007-08-23 ZA ZA200707136A patent/ZA200707136B/xx unknown
- 2007-08-23 TN TNP2007000323A patent/TNSN07323A1/en unknown
- 2007-09-13 NO NO20074666A patent/NO20074666L/no not_active Application Discontinuation
- 2007-09-24 MA MA30233A patent/MA29433B1/fr unknown
-
2011
- 2011-02-03 CY CY20111100115T patent/CY1111154T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200701802A1 (ru) | Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2 | |
| CY1119669T1 (el) | Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης | |
| CY1122646T1 (el) | Δικυκλικες ετεροαρυλ ενωσεις | |
| DE60230890D1 (de) | Indolizine als kinaseproteinhemmer | |
| CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| CY1107301T1 (el) | Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3 | |
| CY1113924T1 (el) | Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| DK2074122T3 (da) | Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer | |
| CY1114690T1 (el) | Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων | |
| CY1111628T1 (el) | Υποκατεστημενες ενωσεις δικυκλολακταμης | |
| NO20053600D0 (no) | Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer. | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| CY1113314T1 (el) | (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης | |
| EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
| WO2007097981A3 (en) | Alpha carbolines and uses thereof | |
| DK1814880T3 (da) | Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed | |
| TN2010000045A1 (en) | Novel herbicides | |
| BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
| EA201001348A1 (ru) | Пирролопиримидинкарбоксамиды | |
| MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
| EA200601589A1 (ru) | Производные 7h-8,9-дигидропирано-(2,3-c)имидазо(1,2a)пиридина и их применение в качестве ингибиторов секреции кислоты желудочного сока | |
| GT200600349A (es) | Compuestos orgánicos | |
| NO20061343L (no) | Imidazo[4,5-b]pyridinderivater som induserbare NO-syntaseinhibitorer |